Genetic and genomic analysis of lung cancer has yielded many important observations in recent years, including the identification of activating mutations in the epidermal growth factor receptor (EGFR) by this SPORE'S investigators. Recent studies have made it clear that there are numerous targets for both inactivating and activating mutations during lung cancer development, and there is steady progress in unraveling the nature and collective effect of these mutations on the pathogenesis of lung cancer. Genomic technologies have continued to develop at an impressive pace for the past 5-10 years, and it is expected that rapid technological progress will continue for at least the foreseeable future. These new technologies, approaches, and concepts require a high level of understanding and expertise for them to be applied for the most rapid progress by Lung SPORE investigators in their respective projects. This core will facilitate that use in several ways. First, it will provide access to state-of-the-art genomic technologies, with access to new technologies and approaches as they are developed, some of which cannot be foreseen at this time.- Second, it will provide a high level of technical expertise in the application of these technologies, from laboratories with extensive experience with new and emerging technologies. Third, it will provide intellectual strength from seasoned genomics investigators to help SPORE investigators navigate choices among different technologies. Fourth, it will provide state-of-the-art bioinformatics and statistical support for SPORE projects. Fifth, through centralization of genomic data sets and provision of bioinformatics tools for SPORE projects, there will be synergies in data storage and sharing, enabling better integration of ideas and information across the various projects within the SPORE. More specifically, the Genomics and Bioinformatics Core will deploy these resources to assist research progress by Lung SPORE investigators via three specific aims.
Aim 1 : To assist SPORE projects with access to and guidance in the use of genomic and related technologies for utilization in SPORE research projects.
Aim 2 : To support Lung SPORE investigators with bioinformatics and related expertise for design, data handling, and analysis of genomic studies.
Aim 3 : To support data sharing within the DF/HCC Lung SPORE and the greater lung cancer research community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090578-07
Application #
7888234
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
7
Fiscal Year
2009
Total Cost
$123,883
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Zhou, Fei; Wang, Yanru; Liu, Hongliang et al. (2017) Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs. Mol Carcinog 56:1227-1238
Rangachari, Deepa; Costa, Daniel B (2017) Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease. Transl Cancer Res 6:S151-S157

Showing the most recent 10 out of 263 publications